Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Soricimed Biopharma adds deep public markets experience to team with appointment of healthcare veteran Frank Michalargias as CFO

Frank Michalargias Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO. In a finance and operations leadership career spanning more than 25...

May 16, 2022

Markets

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

May 16, 2022

Developments

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

Lanier Biotherapeutics will present a poster demonstrating the ability of its LNR 125 to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the American Thoracic...

May 13, 2022

Markets

BTIG slashes 89bio PT to $28 from $60

BTIG reduced its price target for 89bio (NASDAQ:ETNB) to $28 from $60 but maintained its “buy” rating after making model updates and increasing its modeled discount rate to 14% from 12%. The stock closed at $2.67 on May...

May 13, 2022

Markets

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

May 13, 2022

Markets

BTIG halves Poseida Therapeutics PT to $20 from $40

BTIG slashed its price target for Poseida Therapeutics (NASDAQ:PSTX) to $20 from $40 but maintained its “buy” rating after increasing its modeled discount rate to 14% from $12, given current market conditions. The stock...

May 13, 2022

Developments

NeoTX acquires InterX to boost drug discovery

Closely-held NeoTX of Israel has acquired InterX, a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel...

May 12, 2022

Developments

Check-Cap initiates U.S. pivotal trial of C-Scan

Check-Cap (NASDAQ:CHEK) initiated its U.S. pivotal trial of C-Scan to detect polyps before they become colorectal cancer at the Mayo Clinic in Rochester, Minn. The company has obtained Institutional review board...

May 11, 2022

Developments

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...

May 11, 2022

Markets

Leede Jones Gable starts ProMIS at speculative buy; PT 50 cents (Canadian)

Leede Jones Gable initiated coverage of ProMIS Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents (Canadian). The stock closed at 11 cents on May 10. The firm’s lead preclinical...

May 11, 2022

Markets

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

May 10, 2022

Markets

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

May 10, 2022

Subscribe